Detalhe da pesquisa
1.
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Blood
; 141(14): 1675-1684, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36542826
2.
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Future Oncol
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547003
3.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet
; 399(10343): 2294-2308, 2022 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717989
4.
Long-term follow-up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma-derived factor VIII (Koate) that contains ADAMTS13.
Haemophilia
; 29(6): 1638-1645, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855744
5.
Metabolic Dysregulation Explains the Diverse Impacts of Obesity in Males and Females with Gastrointestinal Cancers.
Int J Mol Sci
; 24(13)2023 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37446025
6.
Non-seminomatous mediastinal germ cell tumor and acute megakaryoblastic leukemia.
Ann Hematol
; 96(9): 1435-1439, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28578457
7.
Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study.
J Oncol Pharm Pract
; 25(3): 762-764, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29690815
8.
Sustained response to lenalidomide for early relapsed marginal zone lymphoma.
Blood Cells Mol Dis
; 71: 53-54, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29496374
9.
Harnessing the PD-1 Pathway in Myelodysplastic Syndrome.
Am J Ther
; 25(6): e711-e712, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29394170
10.
Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma.
Am J Ther
; 25(3): e394-e396, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29557803
11.
Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study.
Am J Ther
; 25(6): e767-e768, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29746291
12.
Degloving the Feet: A Severe Case of Hand-Foot Syndrome After Induction Chemotherapy.
J Cutan Med Surg
; 22(6): 609, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30322303
13.
Impact of primary organ site of involvement by peripheral T-cell lymphoma not otherwise specified on survival.
Cancer Med
; 12(24): 21770-21778, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38073461
14.
Impact of Race and Age and their Interaction on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 23(5): 379-384, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36813625
15.
A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).
EJHaem
; 4(2): 370-380, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37206279
16.
Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma: Recent Advances and Outcomes.
J Pers Med
; 12(2)2022 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35207613
17.
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
Blood Adv
; 6(23): 5969-5979, 2022 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36149968
18.
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma With Extraintestinal Areas of Peripheral T-Cell Lymphoma Involvement.
Cureus
; 12(8): e10021, 2020 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32983716
19.
Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy.
Future Sci OA
; 6(7): FSO581, 2020 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32802390
20.
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.
Nat Med
; 25(1): 141-151, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30420753